|
1
|
Hedvat M, Huszar D, Herrmann A, Gozgit JM,
Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, et
al: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and
oncogenesis in solid tumors. Cancer Cell. 16:487–497. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang S: Regulation of metastases by
signal transducer and activator of transcription 3 signaling
pathway: Clinical implications. Clin Cancer Res. 13:1362–1366.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koppikar P, Lui VW, Man D, Xi S, Chai RL,
Nelson E, Tobey AB and Grandis JR: Constitutive activation of
signal transducer and activator of transcription 5 contributes to
tumor growth, epithelial-mesenchymal transition and resistance to
epidermal growth factor receptor targeting. Clin Cancer Res.
14:7682–7690. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park KW, Kundu J, Chae IG, Kim DH, Yu MH,
Kundu JK and Chun KS: Carnosol induces apoptosis through generation
of ROS and inactivation of STAT3 signaling in human colon cancer
HCT116 cells. Int J Oncol. 44:1309–1315. 2014.PubMed/NCBI
|
|
5
|
Shen A, Chen Y, Hong F, Lin J, Wei L, Hong
Z, Sferra TJ and Peng J: Pien Tze Huang suppresses IL-6-inducible
STAT3 activation in human colon carcinoma cells through induction
of SOCS3. Oncol Rep. 28:2125–2130. 2012.PubMed/NCBI
|
|
6
|
Lee J, Kim JC, Lee SE, Quinley C, Kim H,
Herdman S, Corr M and Raz E: Signal transducer and activator of
transcription 3 (STAT3) protein suppresses adenoma-to-carcinoma
transition in Apcmin/+ mice via regulation of Snail-1 (SNAI)
protein stability. J Biol Chem. 287:18182–18189. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Musteanu M, Blaas L, Mair M, Schlederer M,
Bilban M, Tauber S, Esterbauer H, Mueller M, Casanova E, Kenner L,
et al: Stat3 is a negative regulator of intestinal tumor
progression in Apc min mice. Gastroenterology. 138:1003–1011. 2010.
View Article : Google Scholar
|
|
8
|
Chen W, Zheng R, Zhang S, Zhao P, Zeng H,
Zou X and He J: Annual report on status of cancer in China, 2010.
Chin J Cancer Res. 26:48–58. 2014.PubMed/NCBI
|
|
9
|
Marisa L, de Reyniès A, Duval A, Selves J,
Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D,
Ayadi M, et al: Gene expression classification of colon cancer into
molecular subtypes: Characterization, validation, and prognostic
value. PloS Med. 10:e10014532013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang R, Wang H, Deng L, Hou J, Shi R, Yao
M, Gao Y, Yao A, Wang X, Yu L and Sun B: IL-22 is related to
development of human colon cancer by activation of STAT3. BMC
Cancer. 13:592013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ikezoe T, Chen SS, Tong XJ, Heber D,
Taguchi H and Koeffler HP: Oridonin induces growth inhibition and
apoptosis of a variety of human cancer cells. Int J Oncol.
23:1187–1193. 2003.PubMed/NCBI
|
|
12
|
Wang L, Zhao WL, Yan JS, Liu P, Sun HP,
Zhou GB, Weng ZY, Wu WL, Weng XQ and Sun XJ: Eriocalyxin B induces
apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK
signaling pathways and triggers degradation of AML1-ETO oncoprotein
in a caspase-3-dependent manner. Cell Death Differ. 14:306–317.
2007. View Article : Google Scholar
|
|
13
|
Leizer AL, Alvero AB, Fu HH, Holmberg JC,
Cheng YC, Silasi DA, Rutherford T and Mor G: Regulation of
inflammation by the NF-κB pathway in ovarian cancer stem cells. Am
J Reprod Immunol. 65:438–447. 2011. View Article : Google Scholar
|
|
14
|
Li L, Yue GG, Lau CB, Sun H, Fung KP,
Leung PC, Han Q and Leung PS: Eriocalyxin B induces apoptosis and
cell cycle arrest in pancreatic adenocarcinoma cells through
caspase- and p53-dependent pathways. Toxicol Appl Pharmacol.
262:80–90. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang YW, Jiang XX, Chen QS, Shi WY, Wang
L, Sun HD, Shen ZX, Chen Z, Chen SJ and Zhao WL: Eriocalyxin B
induces apoptosis in lymphoma cells through multiple cellular
signaling pathways. Exp Hematol. 38:191–201. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takaishi S, Okumura T, Tu S, Wang SS,
Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC:
Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin SY, Lai WW, Chou CC, Kuo HM, Li TM,
Chung JG and Yang JH: Sodium ascorbate inhibits growth via the
induction of cell cycle arrest and apoptosis in human malignant
melanoma A375.S2 cells. Melanoma Res. 16:509–519. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen HW, Yu SL, Chen JJ, Li HN, Lin YC,
Yao PL, Chou HY, Chien CT, Chen WJ, Lee YT and Yang PC:
Anti-invasive gene expression profile of curcumin in lung
adenocarcinoma based on a high throughput microarray analysis. Mol
Pharmacol. 65:99–110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moghimi-Dehkordi B and Safaee A: An
overview of colorectal cancer survival rates and prognosis in Asia.
World J Gastrointest Oncol. 4:71–75. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frank DA: STAT3 as a central mediator of
neoplastic cellular transformation. Cancer Lett. 251:199–210. 2007.
View Article : Google Scholar
|
|
22
|
Rivat C, Rodrigues S, Bruyneel E, Piétu G,
Robert A, Redeuilh G, Bracke M, Gespach C and Attoub S: Implication
of STAT3 signaling in human colonic cancer cells during intestinal
trefoil factor 3 (TFF3)- and vascular endothelial growth
factor-mediated cellular invasion and tumor growth. Cancer Res.
65:195–202. 2005.PubMed/NCBI
|
|
23
|
Lu Y, Chen B, Song JH, Zhen T, Wang BY, Li
X, Liu P, Yang X, Zhang QL, Xi XD, et al: Eriocalyxin B ameliorates
experimental autoimmune encephalomyelitis by suppressing Th1 and
Th17 cells. Proc Natl Acad Sci USA. 110:2258–2263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leung CH, Grill SP, Lam W, Gao W, Sun HD
and Cheng YC: Eriocalyxin B inhibits nuclear factor-kappaB
activation by interfering with the binding of both p65 and p50 to
the response element in a noncompetitive manner. Mol Pharmacol.
70:1946–1955. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Coupland VH, Lagergren J, Lüchtenborg M,
Jack RH, Allum W, Holmberg L, Hanna GB, Pearce N and Møller H:
Hospital volume, proportion resected and mortality from oesophageal
and gastric cancer: A population-based study in England, 2004–2008.
Gut. 62:961–966. 2013. View Article : Google Scholar
|
|
26
|
Camargo MC, Kim WH, Chiaravalli AM, Kim
KM, Corvalan AH, Matsuo K, Yu J, Sung JJ, Herrera-Goepfert R,
Meneses-Gonzalez F, et al: Improved survival of gastric cancer with
tumour Epstein-Barr virus positivity: An international pooled
analysis. Gut. 63:236–243. 2014.
|
|
27
|
Zucker S and Vacirca J: Role of matrix
metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis
Rev. 23:101–117. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Langers A, Verspaget H, Hawinkels L,
Kubben FJ, van Duijn W, van der Reijden JJ, Hardwick JC, Hommes DW
and Sier CF: MMP-2 and MMP-9 in normal mucosa are independently
associated with outcome of colorectal cancer patients. Brit J
Cancer. 106:1495–1498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ahluwalia A, Jones MK, Matysiak-Budnik T
and Tarnawski AS: VEGF and colon cancer growth beyond angiogenesis:
Does VEGF directly mediate colon cancer growth via a non-angiogenic
mechanism? Curr Pharm Design. 20:1041–1044. 2014. View Article : Google Scholar
|
|
30
|
Jayasinghe C, Simiantonaki N, Habedank S
and Kirkpatrick CJ: The relevance of cell type-and tumor
zone-specific VEGFR-2 activation in locally advanced colon cancer.
J Exp Clin Cancer Res. 34:422015. View Article : Google Scholar
|
|
31
|
Kim JE, Patel M, Ruzevick J, Jackson CM
and Lim M: STAT3 activation in glioblastoma: Biochemical and
therapeutic implications. Cancers (Basel). 6:376–395. 2014.
View Article : Google Scholar
|
|
32
|
Cross-Knorr S, Lu S, Perez K, Guevara S,
Brilliant K, Pisano C, Quesenberry PJ, Resnick MB and Chatterjee D:
RKIP phosphorylation and STAT3 activation is inhibited by
oxaliplatin and camptothecin and are associated with poor prognosis
in stage II colon cancer patients. BMC Cancer. 13:4632013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dave B, Landis MD, Tweardy D, Chang JC,
Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D
and Lewis MT: Selective small molecule Stat3 inhibitor reduces
breast cancer tumor-initiating cells and improves recurrence free
survival in a human-xenograft model. PloS One. 7:e302072012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiong H, Du W, Wang JL, Wang YC, Tang JT,
Hong J and Fang JY: Constitutive activation of STAT3 is predictive
of poor prognosis in human gastric cancer. J Mol Med (Berl).
90:1037–1046. 2012. View Article : Google Scholar
|
|
35
|
Lo HW, Cao X, Zhu H and Ali-Osman F:
Constitutively activated STAT3 frequently coexpresses with
epidermal growth factor receptor in high-grade gliomas and
targeting STAT3 sensitizes them to Iressa and alkylators. Clin
Cancer Res. 14:6042–6054. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fletcher S, Turkson J and Gunning PT:
Molecular approaches towards the inhibition of the signal
transducer and activator of transcription 3 (Stat3) protein.
ChemMedChem. 3:1159–1168. 2008. View Article : Google Scholar : PubMed/NCBI
|
